Virus Specific T-Cells (VSTs) are a target therapy that are generated for specific viral antigens. These products are generated from virus-naive or virus-experienced autologous or allogenic sources. Antigens identified as... Antigens identified as an immune target are presented by antigen-presenting cells (APCs) to T-cells along with other molecules that stimulate their growth and activation.
- Mechanism
- Curator reviewed
Administration of VSTs can provide physiological protection against specific infections, especially for patients who are immunocompromised and depleted of T-cells. VSTs are used as an immunotherapy against many infections, including Epstein-Barr virus, adenovirus, BK virus, and human herpesvirus type 6. This type of treatment is also being investigated as a therapy against SARS-Cov-2.
- Also known as
- HLA-matched Virus Specific T Cells · Partially HLA-matched Virus Specific T Cell · Viral Specific T-lymphocytes · VST
- Code names
- Virus Specific T-Cell
What you can answer from here — as of April 23, 2025
Which companies are running trials of Virus Specific T-Cell, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account